Drug-induced sexual dysfunction in men and women
- Helen M Conaglen, John V Conaglen
- Aust Prescr 2013;36:42-5
- 2 April 2013
- DOI: 10.18773/austprescr.2013.021
Many medical conditions and their treatments contribute to sexual dysfunction.
Commonly implicated drugs includ e antihypertensives, antidepressants, antipsychotics and antiandrogens.
Understanding the potential for drug-induced sexual problems and their negative impact on adherence to treatment will enable the clinician to tailor treatments for the patient and his or her partner.
Encouraging a discussion with the patient about sexual function and providing strategies to manage the problem are critical to good clinical care.
Several classes of prescription drugs contribute to sexual dysfunction in men and women (Table 1).1-3 Patients who develop drug-induced sexual dysfunction are more likely to be non-adherent. This has been found with antihypertensives4 and antipsychotics5. The literature has emphasised male sexual problems with less data available on female or couple problems.
Recreational drugs such as alcohol, narcotics, stimulants and hallucinogens also affect sexual function. Short-term use of alcohol affects sexual desire by decreasing inhibitions, but also diminishes performance and delays orgasm and ejaculation. Many substance abusers report better sexual function, but often their partners report the opposite.6
Sexual function consists of the phases of sexual desire, arousal and orgasm. Both men and women can experience problems in any of these phases. Low desire, lack of swelling and lubrication in women, erectile dysfunction, premature, retrograde or absent ejaculation, anorgasmia and painful sex not only affect the individual, but also impact on their partner.
Whether patients report their sexual problems depends on several factors, including whether the patient is comfortable disclosing these problems, and whether the clinician is willing to ask about sexual issues and does so in a sensitive way.7,8 Patients on long-term medications may not be aware that their sexual problems have developed as a result of their treatment. Conversely some may blame their drugs for sexual problems which are due to relationship difficulties or other stressors. Some doctors consider that asking patients if they had noticed any sexual adverse effects from their drugs may 'suggest' them to the patient, and possibly result in non-adherence. Patients attributing their sexual problems to their drugs are less likely to continue the treatment even when necessary for their health.9 The consultation should include discussion of the patient's sexual issues so these can be considered in treatment decisions.
In an international survey, 20% of men using beta blockers (beta adrenoreceptor antagonists) for hypertension had erectile dysfunction.11 Centrally-acting alpha agonists (for example clonidine) and diuretics have also been implicated in impairing sexual function.4 The aldosterone receptor blocker spironolactone also blocks the androgen receptor and is associated with erectile dysfunction and gynaecomastia.
Sexual dysfunction is more common in women with hypertension (before treatment) compared to normotensive women (42% vs 19%).12 Although the sexual effects of antihypertensives have been poorly studied in women, these drugs may have similar adverse effects on the arousal phase as in men, leading to failure of swelling and lubrication. Decreased sexual desire (41% of women) and sexual pleasure (34%) have been reported.13 Alpha adrenergic drugs such as clonidine and prazosin also reduce desire (in a small, randomised trial)14 and arousal15. The angiotensin II receptor antagonist, valsartan, was associated with improved sexual desire and fantasies when compared with the beta blocker atenolol in women with hypertension.16
Aside from the medicine, it is important to be aware of the effects of psychiatric problems on the patient's relationship and address the psychosocial issues.17 Up to 70% of patients with depression have sexual dysfunction, which can affect any phase of sexual activity.18 Reports indicate that 30–80% of women and 45–80% of men with schizophrenia also experience sexual problems.19 In these patients, it may be difficult to distinguish the effects of the illness on sexual function from the effects of the drugs used for treatment.
Many antidepressants cause sexual difficulties.17,20 Selective serotonin reuptake inhibitors and serotonin noradrenaline reuptake inhibitors inhibit desire, cause erectile dysfunction and decrease vaginal lubrication. They also impair orgasm in 5–71% of patients.18,21,22 This adverse effect is used therapeutically to delay premature ejaculation.
Tricyclic antidepressants inhibit sexual desire and orgasm.23,24 The effects of specific drugs vary depending on their mechanism of action. For example, clomipramine causes orgasmic difficulties in up to 90% of patients, while nortriptyline causes more erectile dysfunction but has less effect on orgasm.25
Monoamine oxidase inhibitors are also associated with sexual dysfunction. Although moclobemide was reported to increase sexual desire,24 the doses used in that study were considered subtherapeutic.
Other antidepressants such as venlafaxine and mirtazapine have variable negative effects on all aspects of sexual function. Initial reports on agomelatine in both male and female patients with major depressive disorder suggested significant antidepressant efficacy without significant sexual adverse effects. However, more recent reviews of the sexual effects are conflicting.26,27
Some antipsychotics may affect sexual function more than others (see Table 2).19,28 The only Cochrane review of antipsychotic-induced sexual dysfunction has reported a small number of studies relating to men, but none relating to women.29
Men taking antipsychotics report erectile dysfunction, decreased orgasmic quality with delayed, inhibited or retrograde ejaculation, and diminished interest in sex. Women experience decreased desire, difficulty achieving orgasm, changes in orgasmic quality and anorgasmia. Dyspareunia, secondary to oestrogen deficiency, can result in vaginal atrophy and dryness. Galactorrhea is experienced in both sexes.28
A recent observational study of schizophrenia found that in patients with diminished sexual desire, ziprasidone was preferred over olanzapine.30 The majority of antipsychotics cause sexual dysfunction by dopamine receptor blockade. This causes hyperprolactinaemia with subsequent suppression of the hypothalamic–pituitary–gonadal axis and hypogonadism in both sexes. This decreases sexual desire and impairs arousal and orgasm. It also causes secondary amenorrhoea and loss of ovarian function in women and low testosterone in men.31,32 Although poorly understood, other neurotransmitter pathways including histamine blockade, noradrenergic blockade and anticholinergic effects may also be affected by antipsychotics.
Before commencing dopamine receptor antagonists it is useful to establish a baseline prolactin, as subsequent elevation can then be attributed to the drug. Non-drug induced causes of hyperprolactinaemia such as pituitary tumours should be considered in patients on dopamine receptor antagonists.33
Oral contraceptives decrease circulating free testosterone. It is postulated that this decreases desire in women, although there is little evidence to support this.38 As with other disorders, the impact of social context including the relationship, and fear of pregnancy and sexually transmitted diseases are confounding influences in clinical reports of the impact of oral contraceptives.
Depot medroxyprogesterone acetate, used as a contraceptive in women, can cause weight gain, depression, vaginal atrophy and dyspareunia with decreased libido in up to 15% of women.39-41
The impact of malignancy and its treatment on both the individual and his or her partner can have a significant negative influence on their sexual relationship. Many of the cancer treatments can lead to sexual dysfunction. As common examples, long-acting gonadotrophin-releasing hormone agonists used for prostate and breast cancer result in hypogonadism, with subsequent reduction in sexual desire, erectile dysfunction in men42, vaginal atrophy and dyspareunia in women as well as orgasmic dysfunction.34
Men who present with symptomatic benign prostatic hyperplasia and lower urinary tract symptoms have an increased incidence of sexual dysfunction. Overall, 72.2% of men with lower urinary tract symptoms had erectile dysfunction compared with 37.7% in those without lower urinary tract symptoms.43 Although surgery and various therapies can improve lower urinary tract symptoms, some of these treatments also cause or exacerbate erectile dysfunction and ejaculatory dysfunction.43
Alpha blockers such as doxazosin, tamsulosin, terazosin and alfuzosin for benign prostatic hyperplasia are reported to be no worse than placebo in their effects on sexual function, although tamsulosin was associated with approximately 10% increase in ejaculatory dysfunction in treated men.44
Antiandrogens such as cyproterone acetate, cimetidine, digoxin and spironolactone block the androgen receptor. This reduces sexual desire in both sexes,45 and affects arousal and orgasm.
Steroids such as prednisone used for many chronic inflammatory disorders result in low serum testosterone which reduces sexual desire and causes erectile dysfunction.46 Immunosuppressive drugs such as sirolimus and everolimus are widely used in kidney transplantation and can impair gonadal function and cause erectile dysfunction.47 Protease inhibitors for HIV have also been implicated in sexual dysfunction and cause erectile problems in over half of men taking them.48
Many other drugs including antihistamines, pseudoephedrine, opioids and recreational drugs may cause sexual dysfunction and should be considered when assessing the patient.
Non-drug approaches include therapy with a clinical psychologist who understands sexual dysfunction. A variety of strategies have been tried to reverse drug-induced sexual dysfunction, including drug switching, dose reduction and drug holidays. Taking a phosphodiesterase type 5 inhibitor in anticipation of intercourse has become the standard of care for men.49-51 It improves erections in about 70% of men with hypertension.52 However, phosphodiesterase type 5 inhibitors are contraindicated in men using nitrates and should be used with caution in those on alpha blockers, where postural hypotension can be a problem. In women, sildenafil has shown promise for reversing the inadequate lubrication and delayed orgasm induced by selective serotonin reuptake inhibitors.53
Changing to an alternative drug is recommended for men and women taking antihypertensives. Alpha blockers, ACE inhibitors and calcium channel blockers are not considered to cause erectile dysfunction,54 while several studies have suggested that angiotensin II receptor antagonists may even improve sexual function. Beta 1 -selective beta blockers such as nebivolol may have potential advantages in these patients.55
In patients taking antipsychotics, establish the cause of the hyperprolactinaemia then consider dose reduction or switching to prolactin-sparing drugs. Relationship counselling and addressing patient-specific concerns can be useful.28
In women, oestrogen cream can alleviate local symptoms such as atrophic vaginitis and dyspareunia. If a woman complains of sexual dysfunction while on an injectable progestogen, another form of contraceptive can be considered.34
Suggested solutions to gabapentin-induced anorgasmia include dose reduction, timing of dose away from planned coitus until anorgasmia no longer occurs, substitution with a different medication, and co-administration of other medications.35,36
Understanding both the impact of a disorder and the effects of its treatment on both the patient and their partner are critical to providing good clinical care. It is important for the clinician to acknowledge and encourage discussion regarding sexual function, as well as enquire about the impact of drugs on sexual function. This will ensure patients and their partners understand their sexual difficulties and treatment options.
Conflict of interest: none declared
Clinical psychologist and Senior research fellow
Endocrinologist and Associate professor in Medicine, Sexual Health Research Unit, Waikato Clinical School Faculty of Medical and Health Sciences, University of Auckland